

Dedicated to you

Financial Statements
Ceylon Hospitals PLC

For the 4th Quarter ended 31st March 2022

| Consolidated Statement of Profit or Loss and Other Comprehensive Income | | | | | Accumulated Period of 12 Months | | | |
|--|----------------------------|------------------------------|----------------------------|------------------------------|---------------------------------|------------------------------|----------------------------|------------------------------|
| Group Company | | | | | Gr | Group Company | | |
| | 03 Months | 03 Months | 03 Months | 03 Months | 12 Months | 12 Months | 12 Months | 12 Months |
| | Ended | Ended | Ended | Ended | Ended | Ended | Ended | Ended |
| | 31/03/2022 | 31/03/2021 | 31/03/2022 | 31/03/2021 | 31/03/2022 | 31/03/2021 | 31/03/2022 | 31/03/2021 |
| | Rs. '000 | Rs. '000 | Rs. '000 | Rs. '000 | Rs. '000 | Rs. '000 | Rs. '000 | Rs. '000 |
| Revenue | 2,028,053 | 1,765,997 | 1,173,273 | 1,110,622 | 7,842,882 | 5,545,521 | 5,075,575 | 3,518,805 |
| Cost of Sales | (788,530) | (770,707) | (413,480) | (458,814) | (2,899,164) | (2,051,798) | (1,889,256) | (1,260,972) |
| Gross Profit | 1,239,523 | 995,289 | 759,793 | 651,808 | 4,943,718 | 3,493,723 | 3,186,318 | 2,257,833 |
| Gross Front | 1,239,323 | 993,209 | 139,193 | 031,000 | 4,543,716 | 3,493,723 | 3,100,310 | 2,237,633 |
| Other Operating Income | (18,192) | 36,844 | 12,893 | 26,890 | 25,524 | 62,559 | 39,938 | 45,555 |
| Administrative Expenses | (696,070) | (705,077) | (482,502) | (519,408) | (2,855,028) | (2,337,358) | (2,016,526) | (1,610,286) |
| Other Operating Expenses | (238,122) | (183,337) | (152,573) | (117,353) | (769,595) | (579,085) | (489,665) | (367,844) |
| Results from Operating Activities | 287,139 | 143,720 | 137,611 | 41,938 | 1,344,618 | 639,839 | 720,065 | 325,259 |
| Firm Cont | (21.000) | (21.976) | (14.730) | (20, 421) | (90.5(6) | (06 670) | (70.794) | (00.160) |
| Finance Cost | (21,006) | | (14,728) | (20,421) | (80,566) | (96,679) | (70,786) | (88,169) |
| Finance Income | 26,435 | 17,046 | 4,717 | 7,737 | 81,822 | 50,308 | 253,213 | 216,541 |
| Gain/ (Loss) on Bargain Purchase | (1,235) | | - | - | 10,767 | - | - | |
| Share of Profit of an Equity Accounted Investee | 2,147 | 48,104 | 105 500 | 20.254 | 15,410 | 102,871 | - 002 402 | 452.622 |
| Profit before Taxation | 293,480 | 186,993 | 127,599 | 29,254 | 1,372,051 | 696,339 | 902,492 | 453,632 |
| Taxation | (67,293) | (26,744) | (37,602) | 16,280 | (301,169) | (96,080) | (155,120) | (7,513) |
| Net Profit after Taxation | 226,187 | 160,249 | 89,997 | 45,535 | 1,070,882 | 600,259 | 747,372 | 446,118 |
| Other Comprehensive Income Items will not be reclassified to profit or loss Net Gain / (Loss) on Gratuity Valuation Deferred Tax Reversal on revaluation Deferred Tax Charge on actuarial Gain | 56,265 3,743 (5,440) | 33,235 208,629 (7,618) | 54,510 3,743 (7,631) | 31,090 203,481 (4,353) | 56,265 3,743 (5,440) | 33,235 208,629 (7,618) | 54,510 3,743 (7,631) | 31,090 203,481 (4,353) |
| Impairment of Building Net Gain / (Loss) on Revaluation of Property,Plant and Equipment | _ | _ | _ | _ | - | - | - | - |
| Net Change in Fair Value on Equity Investments at | | | | | | | | |
| FVOCI | (4,991) | 549 | (2,168) | (116) | (2,823) | 3,068 | - | 128 |
| Other Comprehensive Income for the Year | 49,577 | 234,794 | 48,453 | 230,102 | 51,745 | 237,314 | 50,621 | 230,346 |
| T-4-1 Common borner Income for the West | | 207.012 | 100 151 | | 1 100 100 | | | |
| Total Comprehensive Income for the Year | 275,764 | 395,043 | 138,451 | 275,637 | 1,122,627 | 837,572 | 797,993 | 676,464 |
| Profit Attributable to: | | | | | | | | |
| Equity Holders of the Parent | 193,729 | 149,336 | 89,997 | 45,535 | 950,560 | 560,349 | 747,372 | 446,118 |
| Non-Controlling Interest | 32,459 | 10,913 | - | - | 120,323 | 39,910 | , | - |
| Tion controlling interest | 226,187 | 160,249 | 89,997 | 45,535 | 1,070,882 | 600,259 | 747,372 | 446,118 |
| | | -, - | | - , * | , ,,,,,, | -, | <i>,</i> - – | , - |
| Total Comprehensive Income Attributable to: | | | | | | | | |
| Equity Holders of the Parent | 243,098 | 383,337 | 138,451 | 275,637 | 1,002,097 | 796,597 | 797,993 | 676,464 |
| Non-Controlling Interest | 32,666 | 11,706 | - | - | 120,530 | 40,975 | - | - |
| 5 | 275,764 | 395,043 | 138,451 | 275,637 | 1,122,627 | 837,572 | 797,993 | 676,464 |
| | | , - | | | | * | , - | <u> </u> |
| Earnings per Share - Basic | 5.72 | 4.41 | 2.66 | 1.34 | 28.06 | 16.54 | 22.06 | 13.17 |

The above figures are provisional and subject to audit.

Ceylon Hospitals PLC

Consolidated Statement of Financial Position

| GROUP | COMPANY | | GRO | UP | COMP | ANY |
|------------|---------------------------------------|--|------------|------------|-------------------|-------------------|
| Audited | Audited | | Unaudited | Unaudited | Unaudited | Unaudited |
| As at | As at | | As at | As at | As at | As at |
| 31/03/2021 | 31/03/2021 | | 31/03/2022 | 31/03/2021 | 31/03/2022 | 31/03/2021 |
| Rs. '000 | Rs. '000 | | Rs. '000 | Rs. '000 | Rs. '000 | Rs. '000 |
| | | ASSETS | | | | |
| | | Non-Current Assets | | | | |
| 7,714,638 | 5.083.367 | Property, Plant and Equipment | 8,481,203 | 7,714,638 | 5,592,128 | 5,083,367 |
| 214,544 | | Right of Use Assets | 288,954 | 214,544 | 288,954 | 214,544 |
| _ | | Investments in Subsidiary | · - | _ | 1,457,821 | 1,457,591 |
| 109,374 | | Investment in Equity Accounted Investee | - | 109,374 | - | 230 |
| 165,973 | | Other Financial Assets | 279,787 | 165,973 | 70,944 | 66,910 |
| 990 | - | Prepaid Rent | 890 | 990 | ´- | - |
| 8,205,519 | 6,822,642 | | 9,050,834 | 8,205,519 | 7,409,847 | 6,822,642 |
| | | - | | | | |
| | | Current Assets | | | | |
| 535,877 | , | Inventories | 835,149 | 535,877 | 693,571 | 450,475 |
| 237,950 | · · · · · · · · · · · · · · · · · · · | Trade and Other Receivables | 333,127 | 237,950 | 209,062 | 157,209 |
| 155,456 | | Prepayments | 245,104 | 155,456 | 195,053 | 121,194 |
| 2,418 | | Amount Due from Related Parties | 3,748 | 2,418 | 55,247 | 82,769 |
| 1,106,141 | 123,176 | Other Financial Assets | 1,451,388 | 1,106,141 | 659,287 | 123,176 |
| - | - | Tax Refund Due | 15,437 | - | 13,260 | - |
| 640,115 | | _Cash and Cash Equivalents | 871,117 | 640,115 | 129,295 | 225,211 |
| 2,677,958 | 1,160,034 | _ | 3,755,071 | 2,677,958 | 1,954,774 | 1,160,034 |
| 10,883,477 | 7,982,676 | _Total Assets | 12,805,906 | 10,883,477 | 9,364,620 | 7,982,676 |
| | | | | | | |
| | | EQUITY AND LIABILITIES | | | | |
| | | Equity Attributable to Equity holders of the parent | | | | |
| 916,366 | | Stated Capital | 916,366 | 916,366 | 916,366 | 916,366 |
| 2,691,662 | | Revaluation Reserve | 2,695,406 | 2,691,662 | 2,138,287 | 2,134,544 |
| 68,436 | | Fair Value Reserve | 66,145 | 68,436 | 128 | 128 |
| 2,951,439 | | _Revenue Reserves | 3,842,698 | 2,951,439 | 2,672,257 | 1,986,400 |
| 6,627,903 | 5,037,438 | | 7,520,615 | 6,627,903 | 5,727,038 | 5,037,438 |
| 592,626 | - | _Non-Controlling Interests | 726,732 | 592,626 | - | |
| 7,220,530 | 5,037,438 | Total Equity | 8,247,346 | 7,220,530 | 5,727,038 | 5,037,438 |
| | | Non-Current Liabilities | | | | |
| 823,144 | 784 444 | Interest Bearing Loans and Borrowings | 1,682,287 | 823,144 | 1,587,034 | 784,444 |
| 023,144 | | Deferred Revenue | 1,002,207 | 023,144 | 31,470 | 33,261 |
| 242,882 | , | Retirement Benefit Obligations | 177,998 | 242,882 | 156,790 | 217,078 |
| 642,694 | | Deferred Tax Liabilities | 732,776 | 642,694 | 472,250 | 440,809 |
| 1,708,719 | 1,475,592 | - Deterred Tax Elabilities | 2,593,061 | 1,708,719 | 2,247,544 | 1,475,592 |
| 1,700,719 | 1,473,392 | Current Liabilities | 2,373,001 | 1,700,719 | 2,277,577 | 1,473,392 |
| 221,737 | 72 804 | Bank Overdraft | 246,765 | 221,737 | 94,527 | 72,894 |
| 829,176 | | Interest Bearing Loans and Borrowings | 325,273 | 829,176 | 268,043 | 72,894 |
| 671,130 | | Trade and Other Payables | 1,263,979 | 671,130 | 835,132 | 384,716 |
| 55,191 | | Taxation Payable | 1,203,979 | 55,191 | | |
| 176,994 | | Amount Due to Related Parties | 6,613 | 176,994 | 73,282 119,055 | 41,894 176,727 |
| 1,954,228 | 1,469,647 | - Amount Due to Related Larties | 1,965,498 | 1,954,228 | 1,390,039 | 1,469,647 |
| 10,883,477 | | Total Equity and Liabilities | 12,805,906 | 10,883,477 | 9,364,620 | 7,982,676 |
| 10,003,477 | 7,702,070 | = Lown Eduity and Diabilities | 12,000,700 | 10,003,477 | 7,504,020 | 1,702,010 |

The above figures are provisional and subject to audit.

Snd.

R K Thusitha

Chief Financial Officer

The Board of Directors is responsible for the preparation and presentation of these Financial Statements. Signed for and on behalf of the Board by,

Snd. **A E Tudawe**Chairman

Snd.

U D Tudawe Director

17th May 2022

Ceylon Hospitals PLC

- 2 -

CEYLON HOSPITALS PLC STATEMENT OF CHANGES IN EQUITY

| | Stated Capital | Revaluation Reserve | Fair Value Reserve | Accumulated Profits | Total | Non-Controlling Interest | Total |
|---|-------------------|------------------------|-----------------------|------------------------|-----------|-----------------------------|-----------|
| | Rs. | Rs. | Rs. | Rs. | Rs. | Rs. | Rs. |
| Balance as at 31st March 2020 | 916,366 | 2,483,785 | 65,922 | 2,439,753 | 5,905,826 | 587,760 | 6,493,586 |
| Net Profit for the Period | - | - | - | 560,349 | 560,349 | 39,910 | 600,259 |
| Other Comprehensive Income | | | | | | | |
| Deferred Tax Effect on Revaluation Gain | - | 207,877 | - | - | 207,877 | 752 | 208,629 |
| Actuarial Gain on Gratuity Valuation | - | - | - | 32,865 | 32,865 | 370 | 33,235 |
| Deferred Tax Charge on actuarial Loss on Gratuity Valuation | - | - | - | (7,007) | (7,007) | (610) | (7,618) |
| Net Change in Fair Value on Equity Investments at FVOCI | - | - | 2,514 | - | 2,514 | 554 | 3,068 |
| Total Comprehensive Income for the Period | - | 207,877 | 2,514 | 586,206 | 796,597 | 40,975 | 837,572 |
| Transactions with Owners in their capacity as Owners | | | | | | | |
| Share of additional capital attributable to NCI | - | - | - | - | - | 1,750 | 1,750 |
| Dividend Paid - Ordinary Shares | - | - | - | (74,520) | (74,520) | (37,859) | (112,379) |
| | - | - | - | (74,520) | (74,520) | (36,109) | (110,629) |
| Balance as at 31st March 2021 | 916,366 | 2,691,662 | 68,436 | 2,951,439 | 6,627,903 | 592,626 | 7,220,530 |
| Net Profit for the Period | - | - | - | 950,560 | 950,560 | 120,323 | 1,070,882 |
| Other Comprehensive Income | | | | | | | |
| Net Gain/ (Loss) on Gratuity Valuation | _ | - | - | 55,965 | 55,965 | 300 | 56,265 |
| Deferred Tax Effect on Gratuity Valuation | - | - | - | (5,880) | (5,880) | 440 | (5,440) |
| Deferred Tax Effect on Revaluation Gain | - | 3,743 | - | - | 3,743 | - | 3,743 |
| Prior Year Adjustments- Inventory write off | - | - | - | (993) | (993) | (230) | (1,223) |
| Net Profit on equity instruments designnated at fair Value | | | | | | | |
| through other comprehensive income | - | - | (2,291) | - | (2,291) | (532) | (2,823) |
| Total Comprehensive Income for the Period | - | 3,743 | (2,291) | 999,652 | 1,001,104 | 120,300 | 1,121,404 |
| Transactions with Owners in their capacity as Owners | | | | | | | |
| Non-Controlling Interest on Acquisition of Subsidiary | - | - | - | - | - | 127,301 | 127,301 |
| Dividend Paid - Ordinary Shares | - | - | - | (108,393) | (108,393) | (113,496) | (221,888) |
| | - | | • | (108,393) | (108,393) | 13,805 | (94,587) |
| Balance as at 31st March 2022 | 916,366 | 2,695,406 | 66,145 | 3,842,698 | 7,520,615 | 726,732 | 8,247,346 |

Company

| | Stated Capital Rs. | Revaluation Reserve Rs. | Fair Value Reserve Rs. | Accumulated Profits Rs. | Total Rs. |
|---|--------------------------|-------------------------------|------------------------------|-------------------------------|--------------|
| Balance as at 31st March 2020 | 916,366 | 1,931,063 | - | 1,588,064 | 4,435,493 |
| Net Profit for the Period | - | - | - | 446,118 | 446,118 |
| Other Comprehensive Income | | | | | |
| Deferred Tax Effect on Revaluation Gain | _ | 203,481 | - | - | 203,481 |
| Actuarial Gain on Gratuity Valuation | - | · - | - | 31,090 | 31,090 |
| Deferred Tax Effect on Gratuity Valuation | - | - | - | (4,353) | (4,353) |
| Net Change in Fair Value on Equity Investments at FVOCI | - | - | 128.00 | - | 128 |
| Total Comprehensive Income for the Period | - | 203,481 | 128 | 472,855 | 676,464 |
| Transactions with Owners in their capacity as Owners | | | | | |
| Dividend Paid - Ordinary Shares | _ | - | - | (74,520) | (74,520) |
| | - | - | - | (74,520) | (74,520) |
| Balance as at 31st March 2021 | 916,366 | 2,134,544 | 128 | 1,986,400 | 5,037,438 |
| Net Profit for the period | - | - | - | 747,372 | 747,372 |
| Other Comprehensive Income | | | | | |
| Deferred Tax Effect on Revaluation Gain | - | 3,743 | - | - | 3,743 |
| Net Gain/ (Loss) on Gratuity valuation | - | - | - | 54,510 | 54,510 |
| Deferred Tax Effect on Gratuity Valuation | - | - | - | (7,631) | (7,631) |
| Net Gain/ (Loss) on Land and Building valuation | - | - | - | - | - |
| Net Profit on equity instruments designnated at fair- | - | - | - | - | - |
| -Value through other comprehensive income | - | - | - | - | - |
| Total Comprehensive Income for the Period | - | 3,743 | - | 794,250 | 797,993 |
| Transactions with Owners in their capacity as Owners | | | | | |
| Dividend Paid - Ordinary Shares | - | - | - | (108,393) | (108,393) |
| • | - | - | - | (108,393) | (108,393) |
| Balance as at 31st March 2022 | 916,366 | 2,138,287 | 128 | 2,672,257 | 5,727,038 |

Consolidated Statement of Changes in Equity For the period ended 31st March 2021

| ~ | | | |
|----|----|---|---|
| l٠ | ro | m | 1 |
| • | | | • |

| | Stated | Revaluation | Fair Value | Revenue | Total | NCI | Total |
|---|---------|-------------|------------|-----------|-----------|----------|-----------|
| | Capital | Reserve | Reserve | Reserves | _ | - | - |
| | Rs. | Rs. | Rs. | Rs. | Rs. | Rs. | Rs. |
| Balance as at 31st March 2019 | 916,366 | 1,986,853 | 69,939 | 2,169,904 | 5,143,062 | 564,744 | 5,707,805 |
| Net Profit for the Year | - | - | - | 403,274 | 403,274 | 63,819 | 467,093 |
| Other Comprehensive Income | | | | | | | |
| Deferred Tax Effect on Revaluation Gain | - | (186,990) | - | - | (186,990) | (4,091) | (191,080) |
| Deferred Tax Effect on Gratuity valuation | - | - | - | 4,149 | 4,149 | 98 | 4,247 |
| Net Gain/ (Loss) on Gratuity valuation | - | - | - | (15,632) | (15,632) | (490) | (16,122) |
| Net Gain/ (Loss) on Land and Building valuation | - | 683,922 | - | - | 683,922 | 26,413 | 710,335 |
| Net Change in Fair Value on Equity Investments at FVOCI | | - | (4,017) | - | (4,017) | (920) | (4,937) |
| Total Comprehensive Income for the Year | - | 496,933 | (4,017) | 391,791 | 884,706 | 84,830 | 969,536 |
| Transactions with Owners in their capacity as Owners | | | | | | | |
| Dividend Paid - Ordinary Shares | - | - | - | (121,942) | (121,942) | (61,814) | (183,756) |
| · | - | - | - | (121,942) | (121,942) | (61,814) | (183,756) |
| Balance as at 31st March 2020 | 916,366 | 2,483,785 | 65,922 | 2,439,753 | 5,905,826 | 587,760 | 6,493,586 |
| Net Profit for the Period | - | - | = | 560,349 | 560,349 | 39,910 | 600,259 |
| Other Comprehensive Income | | | | | | | |
| Deferred Tax Effect on Revaluation Gain | - | 207,877 | - | - | 207,877 | 752 | 208,629 |
| Net Gain/ (Loss) on Gratuity valuation | - | - | - | 32,865 | 32,865 | 370 | 33,235 |
| Deferred Tax Effect on Gratuity valuation | - | - | - | (7,007) | (7,007) | (610) | (7,618) |
| Net Change in Fair Value on Equity Investments at FVOCI | - | - | 2,514 | - | 2,514 | 554 | 3,068 |
| Total Comprehensive Income for the Period | - | 207,877 | 2,514 | 586,206 | 796,597 | 40,975 | 837,572 |
| Transactions with Owners in their capacity as Owners | | | | | | | |
| Non-Controlling Interest on Acquisition of Subsidiary | - | - | - | - | - | 1,750 | 1,750 |
| Dividend Paid - Ordinary Shares | - | - | - | (74,520) | (74,520) | (37,859) | (112,379) |
| · | - | - | - | (74,520) | (74,520) | (36,109) | (110,629) |
| Balance as at 31st March 2021 | 916,366 | 2,691,662 | 68,436 | 2,951,439 | 6,627,903 | 592,626 | 7,220,530 |

Company

| | Rs. | Rs. | Rs. | | |
|---|---------|-----------|---------|-----------|-----------|
| | 016 266 | | 1101 | Rs. | Rs. |
| Balance as at 31st March 2019 | 916,366 | 1,564,589 | 56 | 1,502,005 | 3,983,016 |
| Net Profit for the Year | - | - | - | 217,404 | 217,404 |
| Other Comprehensive Income | | | | | |
| Deferred Tax Effect on Revaluation Gain | - | (163,081) | - | - | (163,081) |
| Deferred Tax Effect on Gratuity valuation | - | - | - | 3,657 | 3,657 |
| Net Gain/ (Loss) on Gratuity valuation | - | - | - | (13,060) | (13,060) |
| Net Gain/ (Loss) on Land and Building valuation | - | 529,555 | - | - | 529,555 |
| Net Change in Fair Value on Equity Investments at FVOCI | - | - | (56.00) | - | (56) |
| Total Comprehensive Income for the Year | - | 366,474 | (56) | 208,001 | 574,419 |
| Transactions with Owners in their capacity as Owners | | | | | |
| Dividend Paid - Ordinary Shares | - | - | - | (121,942) | (121,942) |
| | - | - | - | (121,942) | (121,942) |
| Balance as at 31st March 2020 | 916,366 | 1,931,063 | - | 1,588,064 | 4,435,493 |
| Net Profit/(Loss) for the period | - | - | - | 446,118 | 446,118 |
| Other Comprehensive Income | | | | | |
| Deferred Tax Effect on Revaluation Gain | _ | 203,481 | - | _ | 203,481 |
| Actuarial Gain/ (Loss) on Gratuity valuation | _ | - | - | 31,090 | 31,090 |
| Deferred Tax Effect on Gratuity valuation | - | - | - | (4,353) | (4,353) |
| Net Change in Fair Value on Equity Investments at FVOCI | - | - | 128 | - | 128 |
| Total Comprehensive Income for the Period | - | 203,481 | 128 | 472,855 | 676,464 |
| Transactions with Owners in their capacity as Owners | | | | | |
| Dividend Paid - Ordinary Shares | - | - | - | (74,520) | (74,520) |
| · | - | - | - | (74,520) | (74,520) |
| Balance as at 31st March 2021 | 916,366 | 2,134,544 | 128 | 1,986,400 | 5,037,438 |

Statement of Cash Flows

| Group | Company | | Gro | un | Compa | nv |
|------------|--------------|---|-------------|------------|-------------|--------------|
| Audited | Audited | | Unaudited | Unaudited | Unaudited | Unaudited |
| 12 Months | 12 Months | | 12 Months | 12 Months | 12 Months | 12 Months |
| Ended | Ended | | Ended | Ended | Ended | Ended |
| 31/03/2021 | 31/03/2021 | | 31/03/2022 | 31/03/2021 | 31/03/2022 | 31/03/2021 |
| Rs '000 | Rs '000 | | Rs '000 | Rs '000 | Rs '000 | Rs '000 |
| KS 000 | KS 000 | Cash Flows from/ (Used in) Operating Activities | KS 000 | KS 000 | NS 000 | KS 000 |
| 696,339 | 152 622 | Net Profit Before Income Tax Expenses | 1,372,051 | 696,339 | 902,492 | 453,632 |
| 090,339 | 433,032 | Net From before income Tax Expenses | 1,372,031 | 090,339 | 902,492 | 455,052 |
| | | Adjustments for: | | | | |
| 6,705 | 5 550 | Inventory Write-off/(Net) | 25,388 | 6,705 | 21,790 | 5,550 |
| 11,335 | | Bad Debts Write-off | 19,489 | 11,335 | 12,010 | 3,545 |
| 354,740 | | Depreciation Charge for the Year | 339,921 | 354,740 | 185,100 | 190,061 |
| 101,892 | | Amortisation of Right to use assets | 108,031 | 101,992 | 106,635 | 101,892 |
| (50,308) | | Finance Income | (81,822) | (50,308) | (253,213) | (216,541) |
| 96,679 | | Finance Cost | 80,566 | 96,679 | 70,786 | 88,169 |
| 100 | | Amortisation of Deferred Rent | 100 | - | (1,790) | (1,790) |
| (5,340) | | (Profit)/ Loss on Disposal of Property, Plant and Equipment | (5,202) | (5,340) | (5,202) | (5,340) |
| 5,412 | | (Increase)/ Decrease in Financial Instruments | (32,917) | 5,412 | (0,202) | 128 |
| (102,871) | - | Share of Profit of an Equity Accounted Investee | (10,767) | (102,871) | _ | - |
| 49,845 | | Provision for Defined Benefit Plans | 28,948 | 49,845 | 25,089 | 43,504 |
| 1,164,528 | | Operating Profit before Working Capital Changes | 1,843,788 | 1,164,528 | 1,063,696 | 662,809 |
| -,, | , | | _,,,,,,,,, | -,, | _,,,,,,,,, | , |
| (162,833) | (147,103) | (Increase)/Decrease in Inventories | (324,660) | (162,833) | (264,887) | (147,103) |
| 80,106 | | (Increase)/Decrease in Trade and Other Receivables | (204,315) | 80,106 | (137,722) | 42,131 |
| 160,669 | | Increase/(Decrease) in Trade and Other Payables | 592,849 | 160,669 | 450,416 | 92,447 |
| 219,127 | | (Increase)/Decrease Related Party Dues | (171,712) | 219,127 | (30,149) | (324,683) |
| 1,461,598 | | Cash Generated from Operations | 1,735,950 | 1,461,598 | 1,081,355 | 325,601 |
| -,, | , | | _,,,, _ , | -,, | _,,, | , |
| (70,135) | (61,624) | Finance Cost Paid | (51,361) | (70,135) | (41,581) | (61,624) |
| (39,020) | (30,438) | Defined Benefit Plan Costs Paid | (37,567) | (39,020) | (30,868) | (30,438) |
| (87,932) | (15,946) | Income Tax Paid | (160,851) | (87,932) | (109,439) | (15,946) |
| 1,264,511 | 217,593 | Net Cash from Operating Activities | 1,486,171 | 1,264,511 | 899,467 | 217,593 |
| | | • | | | | |
| | | Cash Flows from/ (used in) Investing Activities | | | | |
| (384,556) | | Acquisition of Property, Plant and Equipment | (1,114,939) | (384,556) | (702,313) | (299,170) |
| (2,425) | | Acquisition of Right to use assets | (18,968) | (2,525) | (17,572) | (2,425) |
| 13,945 | | Proceeds from Sale of Property, Plant and Equipment | 13,655 | 13,945 | 13,655 | 13,655 |
| (444,441) | (40,159) | (Acquisition)/ Disposal of other Investments | (429,884) | (444,341) | (540,144) | (40,159) |
| 50,308 | | Income from Investments | 81,822 | 50,308 | 253,213 | 216,541 |
| (767,169) | (111,558) | Net Cash Flows from/ (used in) Investing Activities | (1,468,314) | (767,169) | (993,162) | (111,558) |
| | | | | | | |
| | | Cash Flows from/ (used in) Financing Activities | | | | |
| 915,630 | | Receipts from Interest Bearing Loans and Borrowings | 1,019,153 | 915,630 | 900,909 | 890,630 |
| (302,106) | | Re-payments to Interest Bearing Loans and Borrowing | (740,022) | (302,106) | (699,802) | (282,766) |
| (116,569) | (116,569) | Lease Rent Payment | (116,569) | (116,569) | (116,569) | (116,569) |
| 1,750 | - | Proceeds from the Issue of Shares | - | 1,750 | - | - |
| | | Non-Controlling Interest on Acquisition of Subsidiary | 247,442 | | - | |
| (112,379) | | Dividends Paid | (221,888) | (112,379) | (108,393) | (74,520) |
| 386,326 | 416,775 | Net Cash Flows from/ (used in) Financing Activities | 188,116 | 386,326 | (23,854) | 416,775 |
| 002 | 20. 0 | | | - | /a.a.= = a: | - |
| 883,668 | | Net Increase/ (Decrease) in Cash and Cash Equivalents | 205,973 | 883,668 | (117,549) | 522,810 |
| (465,289) | | Cash and Cash Equivalents at the Beginning of the Year | 418,379 | (465,289) | 152,317 | (370,493) |
| 418,379 | 152,317 | Cash and Cash Equivalents at the End of the Year | 624,352 | 418,379 | 34,768 | 152,317 |
| | _ | Analysis of Cash and Cash Equivalents | | _ | | - |
| (221,737) | . , , | Bank Overdraft | (246,765) | (221,737) | (94,527) | (72,894) |
| 640,115 | | Cash in Hand and at Bank | 871,117 | 640,115 | 129,295 | 225,211 |
| 418,379 | 152,317 | <u>.</u> | 624,352 | 418,379 | 34,768 | 152,317 |

Explanatory Notes

01. CORPORATE INFORMATION

Ceylon Hospitals PLC is a public limited company incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. Ordinary shares of the company are listed on the Colombo Stock Exchange.

02. INTERIM CONDENSED FINANCIAL STATEMENTS

The financial statements for the period ended 31 March 2022, includes "the Company" referring to Ceylon Hospitals PLC, as the holding company and "the Group" referring to the companies whose accounts have been consolidated therein.

03. APPROVAL OF FINANCIAL STATEMENTS

The interim condensed financial statements of the Group and the Company for the period ended 31 March 2022 were authorised for issue by the Board of Directors on 10 May 2022.

04. BASIS OF PREPARATION AND CHANGES TO ACCOUNTING POLICIES

4.1 Basis of preparation

The interim financial statements for the period ended 31 March 2022 have been prepared in accordance with LKAS 34 Interim Financial Reporting.

The interim condensed financial statements do not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group's annual consolidated financial statements as at 31 March 2022.

4.2 Fair value measurement and related fair value disclosures

The fair values of all the financial assets and financial liabilities recognised during the quarter were not materially different from the transaction prices at the date of initial recognition. There were no transfers between Level 1 and Level 2 and no transfers into or out of Level 3 categories as per the fair value hierarchy, during the quarter. The fair value changes on financial instruments in Level 3 category was properly recorded in the statement of other comprehensive income and there were no purchases and/or disposals during the period.

Fair valuation was done as of 31 March 2022 for all unquoted equity shares classified as Level 3 within the fair value hierarchy according to fair valuation methodology. Fair value would not significantly vary if one or more of the inputs were changed.

4.3 COVID - 19 impact assessment

The Company has been in continuous operation although at reduced level subject to guidelines set out by the Government of Sri Lanka (GOSL) during the COVID-19 pandemic confirming to the regulations and guidelines issued by the GOSL, Ministry of Health (MOH) and other allied authorities.

Although it is too early to make an assessment, the Company has seen a smooth transition with the resumption of business activities with a positive momentum. Given the volatile and evolving landscape, the Company will continue to monitor the impacts on it's operations and proactively take measures to ensure the business continues as seamlessly as possible.

No circumstances have arisen since the Balance Sheet date, which would require adjustment or disclosure in the interim Financial Statements other than what is stated above.

- 05. There were no contingent liabilities as at the Balance Sheet date which would require adjustment or disclosure in the Financial Statements.
- 06. Related party transactions for the quarter ended 31 March 2022 were reviewed by the Related Party Transactions Review Committee and it was decided there were no transactions requiring Board Approval, immediate CSE disclosure or Shareholder approval.

Cevlon Hospitals PLC

| For the period ended 31 March 2022 In LKR '000s | | | | |
|--|-----------------|---|------------------------|---|
| Name of the Related Party | Relationship | Transactions | Nature | Aggregate Value of Related Party Transactions |
| Durdans Management Services Ltd | Ultimate Parent | Management fee Rendering of utilities and other cost | Recurrent Recurrent | 51,553 - |
| | | Total | | 51,553 |
| Durdans Medical and Surgical Hospital (Pvt) Ltd | Subsidiary | Sales of Drugs and consumables | Recurrent | 32,577 |
| Durdans Medicai and Surgicai Hospitai (1 Vt) Eld | Subsidiary | Rendering of medical services | Recurrent | 325,266 |
| | | Rendering of utilities and other cost | Recurrent | 417,296 |
| | | Purchases of Drugs and consumables | Recurrent | 31,681 |
| | | Receiving of medical services | Recurrent | 624,334 |
| | | Receiving of utilities and other cost | Recurrent | 30,113 |
| | | Total | recurrent | 1,461,267 |
| | | | | |
| Durdans Heart Centre (Pvt) Ltd | Subsidiary | Sales of Drugs and consumables | Recurrent | 3,034 |
| | | Rendering of medical services | Recurrent | 106,247 |
| | | Rendering of utilities and other cost | Recurrent | 82,719 |
| | | Purchases of Drugs and consumables | Recurrent | 9,061 |
| | | Receiving of medical services | Recurrent | 74,686 |
| | | Receiving of utilities and other cost | Recurrent | 8,956 |
| | | Total | | 284,703 |
| Amrak Institute of Medical Sciences (Pvt) Ltd | Subsidiary | Rendering of utilities and other cost | Recurrent | 1,607 |
| Timuak Institute of Frederical Sciences (1 vt) Eta | Subsiciary | Total | Recuirent | 1,607 |
| | | | | 200 540 |
| Ceygen Biotech (Pvt) Ltd | Subsidiary | Purchases of Drugs and consumables | Recurrent | 289,548 |
| | | Receiving of utilities and other cost | Recurrent | 289,548 |
| | | Total | | 269,546 |
| Commercial Marketing Distributors (Pvt) Ltd | Affiliate | Purchases of Drugs and consumables | Recurrent | 114,919 |
| Commercial Marketing Distributors (1 vt) Eta | Ailliate | Total | Recurrent | 114,919 |
| | | | | , |
| Tudawe Brothers (Pvt) Ltd | Affiliate | Rendering of medical services | Recurrent | 1,403 |
| | | Total | | 1,403 |
| | <u> </u> | 1 | 1 | Aggregate Value - C |
| Name of the Related Party | Relationship | Transactions | Nature | Aggregate Value of Related Party Transactions |
| | | | | |
| Tudawe Brothers (Pvt) Ltd | Affiliate | Project 2022 Construction Cost | Non Recurrent | 285,502 |
| | | Total | | 285,502 |

Share Information

Number of Shares Represented in Stated Capital

| Voting Shares | 25,527,272 |
|-------------------|------------|
| Non-Voting Shares | 8,345,454 |
| Total | 33,872,726 |

Public Shareholding as at 31 March 2022

| | Voting | Non-Voting |
|--|-----------------|--------------|
| Number of shareholders | 2,337 | 1,271 |
| Number of shares | 6,030,924 | 4,282,628 |
| Holding Percentage | 23.63% | 51.32% |
| Float Adjusted Market Capitalisation (Rs Mn) | 630 | |
| Float Adjusted Market Capitalisation Option | Less than 2.5 B | n (Option 5) |

Director's and Chief Executive Officer's Shareholding as at 31 March 2022

| | Numbe | Number of Shares | |
|---------------------------------|---------|------------------|--|
| | Voting | Non-Voting | |
| Mr A E Tudawe | 215,052 | - | |
| Mr U D Tudawe | 170,616 | - | |
| Dr A D P A Wijegoonewardene | 220,582 | - | |
| Mr Y N R Piyasena | 501,000 | - | |
| Mr A S Abeyewardene | 1,440 | 1,200 | |
| Mr A D B Talwatte | 1,000 | - | |
| Mr. A.V.R. De Silva Jayatilleke | 100 | - | |
| Mr. A.S. Tudawe | 48 | 1,000 | |
| | | | |

Market Prices recorded during the Quarter

| 2 2000 2000 Quantum | Highest | | Lowest | | Last | |
|---------------------|--------------|-------------------|--------------|------------|--------------|-------------------|
| | Traded Price | | Traded Price | | Traded Price | |
| | 2021/22 | 2020/21 | 2021/22 | 2020/21 | 2021/22 | 2020/21 |
| | Rs | Rs | Rs | Rs | Rs | Rs |
| Voting | 235.00 | 123.00 | 101.50 | 99.00 | 104.50 | 101.25 |
| | 02/02/2022 | <i>07/01/2021</i> | 39/03/2022 | 23/03/2021 | 31/03/2022 | 31/03/2021 |
| Non - Voting | 160.00 | 114.00 | 80.50 | 67.10 | 82.20 | 89.10 |
| | 02/02/2022 | <i>07/01/2021</i> | 30/03/2022 | 24/03/2021 | 30/03/2022 | <i>30/03/2021</i> |

Per Share Ratios

| | Gre | Group | | pany |
|---------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| | As at 31/03/2022 Rs | As at 31/03/2021 Rs | As at 31/03/2022 Rs | As at 31/03/2021 Rs |
| Earnings Per Share | 28.06 | 16.54 | 22.06 | 13.17 |
| Net Asset Per Share | 222.03 | 195.67 | 169.08 | 148.72 |

Top 20 Shareholders Listed as at 31 March 2022

Voting Shareholders

| Name of the Shareholder | Country of | Number of | Holding |
|---|------------|------------|---------|
| | Residence | Shares | % |
| Durdans Management Services Ltd | Sri Lanka | 17,456,507 | 68.38 |
| Lawrance Tudawe Management Services (Pvt) Ltd | do | 600,077 | 2.35 |
| Mr Y N R Piyasena | do | 501,000 | 1.96 |
| Mr Deen Mohamed Fazal Aslam | do | 475,000 | 1.86 |
| Guardian Capital Partners PLC | do | 400,000 | 1.57 |
| Mr Merill J Fernando | do | 367,530 | 1.44 |
| Mr S P Tudawe (Deceased) | do | 307,936 | 1.21 |
| Cargo Boat Development Company PLC | do | 305,485 | 1.20 |
| MJF Holdings Ltd | do | 270,981 | 1.06 |
| Mr DG Wijemanna | do | 243,830 | 0.96 |
| Mr R P Weerasooriya | do | 235,316 | 0.92 |
| Mr A D P A Wijegoonewardene | do | 220,582 | 0.86 |
| Mr A E Tudawe | do | 215,052 | 0.84 |
| Mrs H K Weerasinghe | do | 200,000 | 0.78 |
| Mrs L I Weerasinghe | do | 200,000 | 0.78 |
| Mrs T T Weerasinghe | do | 200,000 | 0.78 |
| Mr U D Tudawe | do | 170,616 | 0.67 |
| Mr A D Tudawe | do | 161,984 | 0.63 |
| Mr R R Tudawe | do | 100,000 | 0.39 |
| Mr A H Munasinghe | do | 86,326 | 0.34 |
| | • | 22,718,222 | 89.00 |

Non-Voting Shareholders

| Name of the Shareholder | Country of Residence | Number of Shares | Holding % |
|---|----------------------|---------------------|-----------|
| Durdans Management Services Ltd | Sri Lanka | 2,666,251 | 31.95 |
| Employee Provident Fund | do | 1,154,371 | 13.83 |
| MJF Holdings Ltd | do | 598,646 | 7.17 |
| E W Balasuriya & Co (Pvt) Ltd | do | 330,619 | 3.96 |
| Mr D Ratnayake | do | 146,866 | 1.76 |
| Mr A H Munasinghe | do | 138,614 | 1.66 |
| Tudawe Engineering Services (Pvt) Ltd | do | 91,986 | 1.10 |
| Mr D A Cabraal | do | 82,500 | 0.99 |
| Mr S S Sithambaranathan | do | 77,753 | 0.93 |
| Mr P S De Mel | do | 70,822 | 0.85 |
| Mr A D Tudawe | do | 70,151 | 0.84 |
| Ms T T Weerasinghe | do | 68,485 | 0.82 |
| Peoples Leasing & Finance PLC /Mr P A I S Perera | do | 65,454 | 0.78 |
| Commercial Bank of Ceylon PLC A/C No 04 | do | 61,100 | 0.73 |
| Mr DP L De Mel | do | 58,908 | 0.71 |
| Saman Villas Limited | do | 58,462 | 0.70 |
| Mr H A Cabraal | do | 50,000 | 0.60 |
| G.D.M. Ranasinghe | do | 50,000 | 0.60 |
| Mr U D Wickremesooriya Jt Mrs S F Wickremesooriya | do | 50,000 | 0.60 |
| Hallsville Trading Group Inc | do | 49,123 | 0.59 |
| - ^ | | 5.940.111 | 71.18 |

CORPORATE INFORMATION

Name of Company

Ceylon Hospitals PLC

Brand Name

DURDANS

Legal Form

A quoted public company with limited liability incorporated in Sri Lanka under the Companies Ordinance No.51 of 1938 and registered under the Companies Act No.07 of 2007.

Company Registration Number

PQ 113

Stocks Exchange Listing

The Ordinary Shares of the Company are listed on the Colombo Stock Exchange of Sri Lanka.

Registered Office

No.03, Alfred Place, Colombo 03.

Bankers

Bank of Ceylon Commercial Bank of Ceylon PLC DFCC Bank PLC Hatton National Bank PLC National Development Bank PLC Nations Trust Bank PLC Sampath Bank PLC Seylan Bank PLC Union Bank PLC People's Bank

Auditors

Messers.B.R.De.Silva & Co. Chartered Accountants No.22/4,Vijaya Kumaratunga Mawatha Colombo 05.

Ceylon Hospitals PLC

Lawyers

Mr.D.F.R.Jayamaha Hector Jayamaha Law Office, No.228,Thimbirigasyaya Road, Colombo 05.

Secretaries

Nexia Corporate Consultants (Pvt) Ltd No 181, Nawala road, Narahenpita.

Registrars

S S P Corporate Services (Pvt) Ltd 546, Galle Road, Colombo 03.